| Ingrezza (valbenazine) / Neurocrine |
NCT05157100: Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia |
|
|
| Completed | 4 | 20 | US | Ingrezza Pill | The Orthopedic Foundation | Cervical Dystonia | 09/23 | 09/23 | | |
NCT05859698: Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia |
|
|
| Active, not recruiting | 4 | 59 | US | Valbenazine, NBI-98854 | Neurocrine Biosciences | Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia | 01/25 | 01/25 | | |
TD-AIDD, NCT06107829: Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities |
|
|
| Withdrawn | 4 | 25 | US | Valbenazine Oral Capsule, Ingrezza | Stephen Ruedrich, Neurocrine Biosciences | Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities | 01/27 | 02/27 | | |
2021-003714-39: Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia |
|
|
| Not yet recruiting | 3 | 400 | Europe | Valbenazine, NBI-98854, Capsule | Neurocrine Biosciences, Inc., Neurocrine Biosciences, Inc. | Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04] | | | | |
NCT04400331: Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease |
|
|
| Active, not recruiting | 3 | 154 | Canada, US | Valbenazine, NBI-98854 | Neurocrine Biosciences, Huntington Study Group | Chorea, Huntington | 03/26 | 03/26 | | |
NCT05206513: Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy |
|
|
| Recruiting | 3 | 80 | Europe, US, RoW | Placebo, Valbenazine, NBI-98854 | Neurocrine Biosciences | Dyskinesia, Cerebral Palsy | 06/25 | 01/26 | | |
NCT06312189: Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada |
|
|
| Enrolling by invitation | 3 | 7 | Canada | Valbenazine, NBI-98854 | Neurocrine Biosciences | Chorea, Huntington | 04/26 | 04/26 | | |
NCT05110157 / 2021-003714-39: Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine As Adjunctive Treatment for Schizophrenia |
|
|
| Active, not recruiting | 3 | 442 | Europe, US, RoW | Placebo, Valbenazine, NBI-98854 | Neurocrine Biosciences, Neurocrine Biosciences, Inc. | Schizophrenia | 03/25 | 03/25 | | |
NCT05654870: Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia |
|
|
| Terminated | 3 | 8 | US | Valbenazine, NBI-98854, Placebo | Neurocrine Biosciences | Schizophrenia | 11/23 | 11/23 | | |
NCT06771323: Safety and Effectiveness of Valbenazine as Adjunct Therapy to Botulinum Toxin Injections in Cervical Dystonia |
|
|
| Not yet recruiting | 2 | 20 | US | Valbenazine, Placebo | Virginia Commonwealth University, Neurocrine Biosciences | Cervical Dystonia | 01/26 | 01/26 | | |
NCT05207085: Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults |
|
|
| Recruiting | 2 | 20 | US | Valbenazine Oral Capsule, Ingrezza, Placebo Oral capsule | Yale University, Neurocrine Biosciences | Trichotillomania (Hair-Pulling Disorder) | 10/25 | 10/26 | | |
NCT05053321: Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine |
|
|
| Recruiting | 1 | 15 | US | Valbenazine | Yale University, Neurocrine Biosciences | Tardive Dyskinesia | 10/25 | 10/25 | | |
